Eight countries have temporarily suspended vaccinations using the treatment developed by the University of Oxford and AstraZeneca over growing concerns of blood clot complications.

AstraZeneca has said a review of all available safety data from more than 17 million vaccinated people in the EU had shown “no evidence of an increased risk” of blood clots in any age group, gender, batch of shots or particular country.